Table 1.
Applied Cells | First Author | Reference | Patients (n) | MS Type (n) | Age | Females (n) | EDSS (before Treatment) | Follow-Up Duration (Months) | Outcome (Beneficial Effects) ****, % | ||
---|---|---|---|---|---|---|---|---|---|---|---|
PPMS | RRMS | SPMS | |||||||||
HSC (auto) | Burt | 17 | 52 | 52 | 35.6 ** | 34 | 3.4 ** | 33.6 ** | 93 | ||
Gale | 46 | 426 | ND | 47 * | 281 | ND | ND | ND | |||
Moore | 45 | 35 | 20 | 15 | 37 * | 24 | 6 * | 36 * | 37 | ||
Ruiz-Arguelles | 44 | 617 | 130 | 259 | 228 | 46 * | 401 | 5.5 * | 3–42 | 18 | |
Ruiz-Arguelles | 43 | 286 | 62 | 110 | 114 | 47 * | 194 | 5 * | 3 ** | 16 | |
Atkins | 42 | 24 | 12 | 12 | 34 * | 14 | 4.9 ** | 80.4 ** | 71 | ||
Mancardi | 41 | 9 | 2 | 7 | 36 * | 5 | 6.5 * | 48 ** | 100 | ||
Nash | 40 | 25 | 25 | 37.3 ** | 17 | 4.4 ** | 46.5 ** | 69 | |||
Berard | 38 | 23 | 12 | 11 | 32.65 ** | 14 | 4.87 ** | 36 ** | ND | ||
Walker | 39 | 7 | 7 | 37.4 ** | ND | 4.64 ** | 24 ** | ND | |||
Shevchenko | 37 | 95 | 15 | 45 | 35 | 34.5 ** | 59 | 3.5 * | 46 ** | 100 | |
Hamerschlak | 36 | 41 | 4 | 4 | 33 | 42 ** | 24 | 6.5 * | 36 ** | 59 | |
Burt | 35 | 21 | 21 | 33 ** | 11 | 3.1 ** | 37 * | 100 | |||
Capello | 34 | 21 | 4 | 17 | 36 * | ND | 6.5 * | ND | 95 | ||
Saccardi | 33 | 19 | 4 | 15 | 36 * | 12 | 6.5 * | 36 * | 95 | ||
Saiz | 32 | 14 | 5 | 9 | 30 * | 12 | 6 * | 36 * | 86 | ||
Burt | 31 | 21 | 6 | 1 | 14 | 38.9 ** | 10 | 6.4 ** | 26 ** | 62 | |
Espigado | 29 | 22 | Progressive MS (ND) | ND | ND | ND | 10 * | 77 | |||
Nash | 30 | 26 | 8 | 1 | 17 | 41 * | 12 | 7 * | 28 * | 77 | |
Mancardi | 28 | 10 | 10 | 37.1 ** | 5 | 6.5 * | 15 * | 60 | |||
Saiz | 27 | 5 | 2 | 3 | 33.6 ** | 4 | 6.5 * | 18 * | 60 | ||
Fassas | 26 | 24 | 8 | 16 | 40 * | 12 | 6 * | 40 * | 75 | ||
Kozak | 25 | 11 | 11 | 35.7 ** | 9 | 6.7 ** | 8.5 * | 91 | |||
Fassas | 24 | 15 | 8 | 7 | 37 * | 7 | 6 * | 6 * | 93 | ||
MSC (auto) | Uccelli | 62 | 144 | 17 | 94 | 33 | 39 ** | 87 | 4 * | 5.6 *** | 87 |
Petrou | 61 | 48 | 7 | 41 | 47.63 ** | 21 | 5.6 ** | 12 *** | 35 | ||
Sahraian | 60 | 4 | 1 | 3 | 28 ** | 1 | 4.25 ** | 24 *** | 75 | ||
Cohen | 57 | 25 | 11 | 14 | 46.4 ** | 17 | 6 * | 6 *** | 72 | ||
Fernandez | 65 | 19 | 19 | 46 ** | 13 | 7.5 * | 12 *** | 100 | |||
Harris | 59 | 20 | 4 | 16 | 49 ** | 14 | 6.8 ** | 6 *** | 40 | ||
Dahbour | 58 | 10 | 2 | 8 | 34.9 ** | 4 | 5.1 ** | 12 *** | 60 | ||
Harris | 56 | 6 | 2 | 4 | 42.7 ** | 4 | 7.3 ** | 88.8 ** | 100 | ||
Stepien | 64 | 20 | 13 | 7 | 38 ** | 8 | 5 * | 18 *** | 100 | ||
Llufriu | 55 | 9 | 9 | 36.8 ** | 7 | 3.5 * | 13 * | 89 | |||
Bonab | 54 | 25 | 2 | 23 | 37.7 ** | 19 | 6.1 ** | 12 *** | 16 | ||
Connick | 53 | 10 | 10 | 48.8 ** | 3 | 6.1 ** | 18 *** | ND | |||
Hammadi | 63 | 50 | Progressive MS (ND) | 44 ** | 25 | 7 | 12 *** | 48 | |||
Karussis | 52 | 15 | Progressive MS (ND) | 35.3 ** | 8 | 6.7 ** | 6–25 | 100 | |||
Yamout | 51 | 10 | 1 | 9 | 38.5 ** | 6 | 4-7.5 | 12 *** | 70 | ||
Bonab | 50 | 10 | 2 | 8 | 33 ** | 77 | 3.5–6 | 19 ** | 60 | ||
MSC (allo) | Roirdan | 68 | 20 | 4 | 15 | 1 | 41.15 ** | 12 | 5.23 ** | 12 *** | 100 |
Li | 66 | 13 | RRMS/SPMS (ND) | 41.7 ** | 9 | 6.98 ** | 12 *** | ND | |||
Lublin | 67 | 16 | 10 | 6 | 48 * | 11 | 4.8 ** | 12 *** | 94 | ||
Peptide-loaded tolerogenic
dendritic cells (auto) |
Zubizarreta | 9 | 8 | 3 | 1 | 4 | 49.25 ** | 4 | 5.9 ** | 3 *** | 100 |
MS = multiple sclerosis; PPMS = primary progressive MS; RRMS = relapsing–remitting MS; SPMS = secondary progressive MS; EDSS = expanded disability status scale; HSC = hematopoietic stem cell; MSC = mesenchymal stem cell; auto = autologous; allo = allogeneic; * = median; ** = mean; *** = predefined follow-up duration; **** = improvement in or stability of EDSS scores during follow-up; ND = no data.